A preclinical and clinical overview of the nucleotide-based antiviral agent cidofovir (HPMPC)

Advances in Experimental Medicine and Biology

Volumn 394, Issue , 1996, Pages 105-115

  Lalezari, Jacob P ^b   Stagg, Robert J ^b   Jaffe, Howard S ^b   Hitchcock, Michael J M ^b   Drew, W Lawrence ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; CIDOFOVIR; DRUG METABOLITE; FOSCARNET; GANCICLOVIR; NUCLEOTIDE DERIVATIVE; PROBENECID; ZIDOVUDINE;

AIDS RELATED COMPLEX; ALOPECIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONDYLOMA; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; FEVER; GENITAL HERPES; HEADACHE; HERPES VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RASH; RETINITIS; SUBCUTANEOUS DRUG ADMINISTRATION; VOMITING;

CYTOMEGALOVIRUS; HERPES; HERPESVIRIDAE; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0029864036     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4757-9209-6_12     Document Type: Conference Paper

References (23)

1. De Clercq E, Sakuma T, Baba M. et al. Antiviral activity of phosphonylmethoxyalkyl derivatives of purines and pyrimidines. Antiviral Res 8:261-272, 1987.
2. Bronson J J, Ghazzouli I, Hitchcock M J M, Webb II R R and Martin J C. Synthesis and antiviral activity of the nucleotide analogue (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine J Med Chem 32:1457-1463, 1989.
3. Martin J C and Hitchcock M J M. Phosphomethylether compounds as antiviral agents. Trans Proc 23:156-158, 1991.
4. Connelly M, Robbins B, and Fridland A. Mechanism of Uptake of the Phosphonate Analog (S)-1(3-Hydroxy-2-phosphonylmethoxy-propyl)cytosine (HPMPC) in Vero Cells. Biochemical Pharmacology 1993, 46:1043.
5. Biron K K, Stanet S C, Sorrell J B, et al Metabolic activation of the nucleoside analog 9-[2-hydroxy-1-(hydroxymethyl)ethoxy]methylguanine in human diploid fibroblasts infected with human cytomegalovirus. Proc Nat. Acad. Sci. USA 82:2473-2477, 1985.
6. Ho H T, Woods KL, Bronson J J, et al. Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. Molec. Pharm. 41:197-202, 1991.
7. Li S B, Yang Z-H, Feng J S, et al. Activity of (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine (HPMPC) against guinea pig cytomegalovirus infection in cultured cells and in guinea pigs. Antiviral Res. 13:237-252, 1990.
8. Snoeck R, Sakuma T, De Clercq E, Rosenberg I and Holy A. (S)-1-[3-hydroxy-2-(phosphonymethoxy)propyl]cytosine, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob. Agents and Chemo 32:1839-1844, 1988.
9. Study DAVI-TJ-21693 "Multiple dose subcutaneous nephrotoxicity study in male guinea pigs" (Data on file at Gilead Sciences, Inc.)
10. Study DAVI-MH-21596, "BMY-41671 (HPMPC). "Multiple dose intravenous nephrotoxicity screening study with probenecid in male rabbits." (Data on file at Gilead Sciences, Inc.)
11. Study TSI 2-T01, "Thirteen week repeated dose toxicity study of HPMPC (GS-504) administered intraveously to cynomolgus monkeys in combination with orally administered probenecid." (Data on file at Gilead Sciences, Inc.)
12. Study TSI 2T70, "Twenty-six week repeat dose study of GS-504 (HPMPC) administered subcutaneously to rats." (Data on file at Gilead Sceiences, Inc.)
13. Study TSI 2-P50, "Thirteen week repeated dose toxicity study of HPMPC administered intravenously to Sprague-Dawley Rats." (Data on file at Gilead Sciences, Inc.)
14. Study TSI 2-P51, "Thirteen week repeated dose toxicity study of HPMPC administered intravenously to cynomolgus monkeys." (Data on file at Gilead Sciences, Inc.)
15. Study 94-DDM-0504-004, "Tissue distribution of 14C-HPMPC (cidofovir) at 6 and 24 hours after single dose administration to female Sprague-Dawley Rats". (Data on file at Gilead Sciences, Inc.)
16. Kern E R. Value of animal models to evaluate agents with potential activity against human cytomegalovirus. Trans. Proc. 23:152-155, 1991.
17. Lalezari JP, Drew WL, Glutzer E, et al. Cidofovir (HPMPC): Results of a phase I/II study of a novel antiviral nucelotide analogue. J. Infectious Dis (In Press)
18. Cundy KC. A report on the effect of cidofovir on the pharmacokinetics of AZT - Johns Hopkins Data. (Data on file at Gilead Sciences, Inc.).
19. Abrams D, Goldman A, Launer C, et al. A comparative trial of didanosine and zalcitabine after treatment with zidovudine in patients with human immunodeficincy virus infection. New England J Med 330:657-662, 1994.
20. Studies of the Ocular Complications of AIDS (SOCA) database (analysis performed by Gilead Sciences, Inc.).
21. Stavudine (d4T) Investigator's Brochure, July 1994.
22. Kuppermann B, Lalezari J, Stagg R, et al. A phase II/III randomised study of immediate versus deferred intravenous cidofovir for AIDS patients with peripheral CMV retinitis. International Symposium on Experimental and Clinical Ocular Pharmacology and Pharmaceutics. 1995 (abstract).
23. Lalezari J, Holland G, Stagg R. et al. A randomized controlled study of cidofovir for relapsing cytomegalovirus retinitis in patients with AIDS. 35th International Conference on Antimicrobial Agents and Chemotherapy, Program Addendum LB-9, 1995 (abstract).